https://doi:10.1002/path.1129. Nakopoulou, L., Giannopoulou, I., Lazaris, A., Alexandrou, P., Tsirm-pa, I., Markaki, S., Panayotopoulou, E., & Keramopoulos, A. (2003). The favorable prognostic impact of tissue inhibitor of matrix metalloproteinases-1 protein overexpression in breast cancer cells. APMIS 2003, 111, 1027-1036. https://doi: 10.1111/j.1600-0463.2003.apm1111105.x. google scholar" />
Research Article
BibTex RIS Cite

Quantification of MMP-2 and TIMP-1 expressions in breast cancer

Year 2023, , 211 - 218, 30.08.2023

Seda Eren Keskin Deniz Sünnetçi Akkoyunlu Mehtap Yılmaz Turgay Şimşek Sertaç Güler Naci Çine Zafer Cantürk Hakan Savlı

https://doi.org/10.26650/IstanbulJPharm.2023.1053089

Abstract

Background and Aims: MMP-2 and TIMP-1 are vital molecules in the remodeling of the extracellular matrix, and they have a critical role in the metastatic process of breast cancer. This study aimed to detect expression levels of MMP-2 and TIMP-1 genes by Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) and identify their potential roles in breast cancer prognosis.
Methods: MMP-2 and TIMP-1 gene expression levels in 17 breast cancer tumor tissues and normal breast tissue were examined. The expression levels of MMP-2 and TIMP-1 were analyzed by qRT-PCR. The association between the expression levels of MMP-2 and TIMP-1 and clinicopathological manifestations of breast cancer was examined.
Results: Lower gene expression levels of MMP-2 and TIMP-1 were detected in tumors compared to the controls. A statistical correlation was not observed between the expression level of MMP-2, TIMP-1, and clinicopathological parameters (tumor grade, lymph node involvement, hormone receptor status).
Conclusion: Our findings have been suggesting that expression profiles of MMP-2 and TIMP-1 might be independent prognostic and predictive biomarkers for breast cancer. These biomarkers are candidate molecules for personalized therapy. MMP-2 and TIMP-1 expression patterns will also aid in the identification of more precise and targeted subgroups of breast cancer.

Keywords

Breast cancer MMP2 metalloproteinase TIMP-1

References

  • Abdollahi, A., Nozarian, Z., & Nazar, E. (2019). Association Between Expression of Tissue Inhibitors of Metalloproteinase-1, Matrix Me-talloproteinase-2, and Matrix Metalloproteinase-9 and Axillary Lymph Nodes Metastasis in Patients with Breast Cancer. Interna-tional Journal of Preventive Medicine, 10, 127. https://doi:10.4103/ ijpvm.IJPVM_355_16 google scholar
  • Arpino, V., Brock, M., & Gill, S. E. (2015). The role of TIMPs in regula-tion of extracellular matrix proteolysis. Matrix Biology: Journal of the International Society for Matrix Biology, 44-46, 247-254. https:// doi.org/10.1016/j.matbio.2015.03.005 google scholar
  • Chen, Y., Wang, X., Chen, G., Dong, C., & Zhang, D. (2015). The Im-pact of Matrix Metalloproteinase 2 on Prognosis and Clinicopath-ology of Breast Cancer Patients : A Systematic Meta-Analysis. Plos One, 10, 1-16. https://doi.org/10.1371/journal.pone.0121404 google scholar
  • Cine, N., Baykal, A.T., Sunnetci, D., Canturk, Z., Serhatli, M., & Savli, H. (2014). Identification of ApoA1, HPX and POTEE genes by omic analysis in breast cancer. Oncology Reports, 32, 1078-1086. https:// doi.org/10.3892/or.2014.3277 google scholar
  • Daniele, A., Abbate, I., Oakley, C., Casamassima, P., Savino, E., Casa-massima, A ... Divella, R. (2016). Clinical and prognostic role of ma-trix metalloproteinase-2, -9 and their inhibitors in breast cancer and liver diseases: A review. International Journal of Biochemistry, 77, 91-101. https://doi: 10.1016/j.biocel.2016.06.002 google scholar
  • Dechaphunkul, A., Phukaoloun, M., Kanjanapradit, K., Graham, K., Ghosh, S., Santos, C., & Mackey, J. R. (2012). Prognostic signifi-cance of tissue inhibitor of metalloproteinase-1 in breast cancer. International Journal of Breast Cancer, 2012, 290854. https://doi. org/10.1155/2012/290854 google scholar
  • Decock, J., Hendrickx, W., Wildiers, H., Christiaens MR, Neven P, Dri-jkoningen M, & Paridaens, R. (2005). Plasma gelatinase levels in patients with primary breast cancer in relation to axillary lymph node status, Her2/neu expression and other clinicopathological variables. Clinical & Experimental Metastasis, 22, 495-502. https:// doi.org/10.1007/s10585-005-3992-2 google scholar
  • Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D.M., Pineros, M., Znaor, A., & Bray, F. (2019). Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International journal of cancer, 144, 1941-1953. https:// doi.org/10.1002/ijc.31937 google scholar
  • Figueira, R. C. S., Gomes, L. R., Neto, J. S., Silva, F.C., Silva, I. D. C. G., &Sogayar M. C. (2009). Correlation between MMPs and their in-hibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer, 11, 1-11. https:// doi:10.1186/1471-2407-9-20. google scholar
  • Guo, X., Wu, Y., Hathaway, H. J., & Hartley, R. S. (2012). Microenvi-romental control of the breast cancer cell cycle. The Anatomical Record, 295, 553-562. https://doi:10.1002/ar.22417 google scholar
  • Hadler-Olsen, E., Winberg, J. O., & Uhlin-Hansen, L. (2013). Matrix metalloproteinases in cancer: Their value as diagnostic and prog-nostic markers and therapeutic targets. Tumor Biology, 34, 20412051. https://doi:10.1007/s13277-013-0842-8 google scholar
  • Hirvonen, R., Talvensaari-Mattila, A., Paakkö, P., & Turpeenniemi-Hujanen, T. (2003). Matrix metalloproteinase-2 (MMP-2) in T(1-2) N0 breast carcinoma. Breast Cancer Research and Treatment, 77, 85-91. https://doi.org/10.1023/a:1021152910976 google scholar
  • Huang, J., Ang, L., Liu, M. Q., Hu, H. G., Wang, J., & Zou, Q. (2014).Serum and tissue expression of gelatinase and Twist in breast cancer. European Review for Medical and Pharmacological Sciences, 18, 2662-2669. google scholar
  • Jezierska, A., & Motyl, T. (2009). Matrix metalloproteinase-2 in-volvement in breast cancer progression: a mini-review. Medical Science Monitor, 15, RA32-RA40. https://pubmed.ncbi.nlm.nih. gov/19182722/ google scholar
  • Kousidou, O, C., Roussidis, A. E., Theocharis, A. D., & Karamanos, N. K. (2004). Expression of MMPs and TIMPs genes in human breast cancer epithelial cells depends on cell culture conditions and is _______________________________ 217associated with their invasive potential. Anticancer Research, 24, 4025-4030. google scholar
  • Kuvaja, P,, Talvensaari-Mattila, A., Paakkö, P,, & Turpeenniemi-Hu-janen, T. (2005). The absence of immunoreactivity for tissue inhib-itor of metalloproteinase-1 (TIMP-1), but not for TIMP-2, protein is associated with a favorable prognosis in aggressive breast carci-noma. Oncology, 68, 196-203. https://doi.org/10.1159/000086774 google scholar
  • Leppa, S,, Saarto, T,, Vehmanen, L,, Blomqvist, C,, & Elomaa, I, A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. (2004). Clinical Cancer Research, 10, 1057-1063. https://doi:10.1158/1078-0432.ccr-03-0047. google scholar
  • Lipton, A., Leitzel, K., Chaudri-Ross, H. A., Evans, D. B., Ali, S. M., Demers L, ...Carney, W. (2008). Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer. Journal of Clinical Oncology, 26, 2653-2658. https:// doi:10.1200/JCO.2007.15.4336 google scholar
  • Lu, L.S., Chen, L., Ding, W. X., Li, K., &Wu, J. J. (2012). Elevated ex-pression of both MDR1 and MMP-2 genes in metastasized lymph node of invasive ductal breast cancer. European Review for Medi-cal and Pharmacological Sciences, 16, 2037-2043. google scholar
  • Mahmood, N. A., Fakhoury, R. M., Yaseen, N. Y., & Moustafa, M. E. ( 2015). Matrix Metalloproteinases MMP2 and MMP9 Expression in Stages II-III Breast Cancer in Iraqi Women. Journal of Biomedical Science, 1, 30-37. google scholar
  • Nakopoulou, L., Giannopoulou, I., Stefanaki, K., Panayotopoulou, E., Tsirma, I., Alexandrou, P.,.. Davaris, P. (2002). Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 ( TIMP-1 ) in breast carcinomas is correlated with adverse prognosis. The Journal of Pathology, 197, 307-313. https://doi:10.1002/path.1129">https://doi:10.1002/path.1129. Nakopoulou, L., Giannopoulou, I., Lazaris, A., Alexandrou, P., Tsirm-pa, I., Markaki, S., Panayotopoulou, E., & Keramopoulos, A. (2003). The favorable prognostic impact of tissue inhibitor of matrix metalloproteinases-1 protein overexpression in breast cancer cells. APMIS 2003, 111, 1027-1036. https://doi: 10.1111/j.1600-0463.2003.apm1111105.x. google scholar
  • Öncel, M. (2012). Matriks Metalloproteinazlar ve Kanser. Euro-pean Journal of Basic Medical Sciences, 2, 91-100. https://doi. org/10.21601/ejbms/9185 google scholar
  • Savlı, H., Aalto, Y., Nagy, B., Knuutila, S.,& Pakkala, S. (2002). Gene expression analysis of 1,25(OH)2D3-dependent differentiation of HL-60 cells: A cDNA array study. British Journal of Haematology, 118, 1065-1070. https://doi:10.1046/j.1365-2141.2002.03734.x google scholar
  • Savlı, H., Karadenizli, A,, Kolaylı, F., Gündeş, S., Özbek, U., & Vahaboğlu, H. (2003). Expression stability of six housekeeping genes: A proposal for resistance gene quantification studies of Pseudomonas aeruginosa by real-time quantitative RT-PCR. Journal of Medical Microbiology, 52, 403-408. https://doi:10.1099/ jmm.0.05132-0 google scholar
  • Sieuwerts, A. M., Usher, P.A., Meijer-van Gelder, M. E., Timmer-mans, M., Martens, J.W., Brünner, N., ...Foakens, J. A. (2007). Con-centrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer. Clinical Chemistry, 53, 1280-1288. https://doi:10.1373/ clinchem.2006.082800. google scholar
  • Talvensaari-Mattila, A., & Paakkö, P., Turpeenniemi-Hujanen, T. (2003) Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. British Journal of Cancer, 89, 12701275. https://doi:10.1038/sj.bjc.6601238 google scholar
  • Talvensaari-Mattila, A., & Turpeenniemi-Hujanen, T. (2005). High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma. Breast Cancer Research and Treatment, 89, 29-34. https://doi.org/10.1007/s10549-004-1006-8 google scholar
  • Ünçel., M, Aköz., G, Yıldırım., Z, Pişkin., G, Değirmenci M, Kahraman DS, . Diniz., G. (2015). Evaluation of clinicopathological features of breast cancer according to the molecular subtypes. Journal of Tepecik Education and Research Hospital, 25, 151-156. https:// doi:10.5222/terh.2015.151 google scholar
  • Wu, Z. S., Wu, Q., Yang, J. H., Wang, H. Q., Ding, X. D., Yang, F., & Xu, X. C. (2008). Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. International Journal of Cancer, 122, 2050-2056. https://doi.org/10.1002/ijc.23337 google scholar
  • Würtz, S. 0., Schrohl, A. S., Mouridsen, H., & Brünner, N. (2008). TIMP-1 as a tumor marker in breast cancer - An update. Acta Oncolog-ica (Madr), 47, 580-590. https://doi:10.1080/02841860802022976. Würtz S. 0., Moller, S., Mouridsen, H., Hertel, P B., Friis, E., & Brünner N. (2008). Plasma and serum levels of tissue inhibitor of metal-loproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study. Molecular & Cellular Proteomics, 7, 424-430. https://doi:10.1074/mcp.M700305-MCP200. google scholar
  • Yadav, L., Puri, N., Rastogi. V., Satpute, P., Ahmad, R., & Kaur, G. (2014). Matrix metalloproteinases and cancer - Roles in threat and therapy. The Asian Pacific Journal of Cancer Prevention, 15, 10851091. http://dx.doi.org/10.7314/APJCP.2014.15.3.1085 google scholar
  • Zhang, M., Teng, X., Guo, X., Li, Z., Han, J., & Yao, L. (2013). Expres-sion of tissue levels of matrix metalloproteinases and their inhibi-tors in breast cancer. The Breast, 22, 330-334. https://doi:10.1016/j. breast.2012.08.002. google scholar

Year 2023, , 211 - 218, 30.08.2023

Seda Eren Keskin Deniz Sünnetçi Akkoyunlu Mehtap Yılmaz Turgay Şimşek Sertaç Güler Naci Çine Zafer Cantürk Hakan Savlı

https://doi.org/10.26650/IstanbulJPharm.2023.1053089

Abstract

References

  • Abdollahi, A., Nozarian, Z., & Nazar, E. (2019). Association Between Expression of Tissue Inhibitors of Metalloproteinase-1, Matrix Me-talloproteinase-2, and Matrix Metalloproteinase-9 and Axillary Lymph Nodes Metastasis in Patients with Breast Cancer. Interna-tional Journal of Preventive Medicine, 10, 127. https://doi:10.4103/ ijpvm.IJPVM_355_16 google scholar
  • Arpino, V., Brock, M., & Gill, S. E. (2015). The role of TIMPs in regula-tion of extracellular matrix proteolysis. Matrix Biology: Journal of the International Society for Matrix Biology, 44-46, 247-254. https:// doi.org/10.1016/j.matbio.2015.03.005 google scholar
  • Chen, Y., Wang, X., Chen, G., Dong, C., & Zhang, D. (2015). The Im-pact of Matrix Metalloproteinase 2 on Prognosis and Clinicopath-ology of Breast Cancer Patients : A Systematic Meta-Analysis. Plos One, 10, 1-16. https://doi.org/10.1371/journal.pone.0121404 google scholar
  • Cine, N., Baykal, A.T., Sunnetci, D., Canturk, Z., Serhatli, M., & Savli, H. (2014). Identification of ApoA1, HPX and POTEE genes by omic analysis in breast cancer. Oncology Reports, 32, 1078-1086. https:// doi.org/10.3892/or.2014.3277 google scholar
  • Daniele, A., Abbate, I., Oakley, C., Casamassima, P., Savino, E., Casa-massima, A ... Divella, R. (2016). Clinical and prognostic role of ma-trix metalloproteinase-2, -9 and their inhibitors in breast cancer and liver diseases: A review. International Journal of Biochemistry, 77, 91-101. https://doi: 10.1016/j.biocel.2016.06.002 google scholar
  • Dechaphunkul, A., Phukaoloun, M., Kanjanapradit, K., Graham, K., Ghosh, S., Santos, C., & Mackey, J. R. (2012). Prognostic signifi-cance of tissue inhibitor of metalloproteinase-1 in breast cancer. International Journal of Breast Cancer, 2012, 290854. https://doi. org/10.1155/2012/290854 google scholar
  • Decock, J., Hendrickx, W., Wildiers, H., Christiaens MR, Neven P, Dri-jkoningen M, & Paridaens, R. (2005). Plasma gelatinase levels in patients with primary breast cancer in relation to axillary lymph node status, Her2/neu expression and other clinicopathological variables. Clinical & Experimental Metastasis, 22, 495-502. https:// doi.org/10.1007/s10585-005-3992-2 google scholar
  • Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D.M., Pineros, M., Znaor, A., & Bray, F. (2019). Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International journal of cancer, 144, 1941-1953. https:// doi.org/10.1002/ijc.31937 google scholar
  • Figueira, R. C. S., Gomes, L. R., Neto, J. S., Silva, F.C., Silva, I. D. C. G., &Sogayar M. C. (2009). Correlation between MMPs and their in-hibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer, 11, 1-11. https:// doi:10.1186/1471-2407-9-20. google scholar
  • Guo, X., Wu, Y., Hathaway, H. J., & Hartley, R. S. (2012). Microenvi-romental control of the breast cancer cell cycle. The Anatomical Record, 295, 553-562. https://doi:10.1002/ar.22417 google scholar
  • Hadler-Olsen, E., Winberg, J. O., & Uhlin-Hansen, L. (2013). Matrix metalloproteinases in cancer: Their value as diagnostic and prog-nostic markers and therapeutic targets. Tumor Biology, 34, 20412051. https://doi:10.1007/s13277-013-0842-8 google scholar
  • Hirvonen, R., Talvensaari-Mattila, A., Paakkö, P., & Turpeenniemi-Hujanen, T. (2003). Matrix metalloproteinase-2 (MMP-2) in T(1-2) N0 breast carcinoma. Breast Cancer Research and Treatment, 77, 85-91. https://doi.org/10.1023/a:1021152910976 google scholar
  • Huang, J., Ang, L., Liu, M. Q., Hu, H. G., Wang, J., & Zou, Q. (2014).Serum and tissue expression of gelatinase and Twist in breast cancer. European Review for Medical and Pharmacological Sciences, 18, 2662-2669. google scholar
  • Jezierska, A., & Motyl, T. (2009). Matrix metalloproteinase-2 in-volvement in breast cancer progression: a mini-review. Medical Science Monitor, 15, RA32-RA40. https://pubmed.ncbi.nlm.nih. gov/19182722/ google scholar
  • Kousidou, O, C., Roussidis, A. E., Theocharis, A. D., & Karamanos, N. K. (2004). Expression of MMPs and TIMPs genes in human breast cancer epithelial cells depends on cell culture conditions and is _______________________________ 217associated with their invasive potential. Anticancer Research, 24, 4025-4030. google scholar
  • Kuvaja, P,, Talvensaari-Mattila, A., Paakkö, P,, & Turpeenniemi-Hu-janen, T. (2005). The absence of immunoreactivity for tissue inhib-itor of metalloproteinase-1 (TIMP-1), but not for TIMP-2, protein is associated with a favorable prognosis in aggressive breast carci-noma. Oncology, 68, 196-203. https://doi.org/10.1159/000086774 google scholar
  • Leppa, S,, Saarto, T,, Vehmanen, L,, Blomqvist, C,, & Elomaa, I, A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. (2004). Clinical Cancer Research, 10, 1057-1063. https://doi:10.1158/1078-0432.ccr-03-0047. google scholar
  • Lipton, A., Leitzel, K., Chaudri-Ross, H. A., Evans, D. B., Ali, S. M., Demers L, ...Carney, W. (2008). Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer. Journal of Clinical Oncology, 26, 2653-2658. https:// doi:10.1200/JCO.2007.15.4336 google scholar
  • Lu, L.S., Chen, L., Ding, W. X., Li, K., &Wu, J. J. (2012). Elevated ex-pression of both MDR1 and MMP-2 genes in metastasized lymph node of invasive ductal breast cancer. European Review for Medi-cal and Pharmacological Sciences, 16, 2037-2043. google scholar
  • Mahmood, N. A., Fakhoury, R. M., Yaseen, N. Y., & Moustafa, M. E. ( 2015). Matrix Metalloproteinases MMP2 and MMP9 Expression in Stages II-III Breast Cancer in Iraqi Women. Journal of Biomedical Science, 1, 30-37. google scholar
  • Nakopoulou, L., Giannopoulou, I., Stefanaki, K., Panayotopoulou, E., Tsirma, I., Alexandrou, P.,.. Davaris, P. (2002). Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 ( TIMP-1 ) in breast carcinomas is correlated with adverse prognosis. The Journal of Pathology, 197, 307-313. https://doi:10.1002/path.1129">https://doi:10.1002/path.1129. Nakopoulou, L., Giannopoulou, I., Lazaris, A., Alexandrou, P., Tsirm-pa, I., Markaki, S., Panayotopoulou, E., & Keramopoulos, A. (2003). The favorable prognostic impact of tissue inhibitor of matrix metalloproteinases-1 protein overexpression in breast cancer cells. APMIS 2003, 111, 1027-1036. https://doi: 10.1111/j.1600-0463.2003.apm1111105.x. google scholar
  • Öncel, M. (2012). Matriks Metalloproteinazlar ve Kanser. Euro-pean Journal of Basic Medical Sciences, 2, 91-100. https://doi. org/10.21601/ejbms/9185 google scholar
  • Savlı, H., Aalto, Y., Nagy, B., Knuutila, S.,& Pakkala, S. (2002). Gene expression analysis of 1,25(OH)2D3-dependent differentiation of HL-60 cells: A cDNA array study. British Journal of Haematology, 118, 1065-1070. https://doi:10.1046/j.1365-2141.2002.03734.x google scholar
  • Savlı, H., Karadenizli, A,, Kolaylı, F., Gündeş, S., Özbek, U., & Vahaboğlu, H. (2003). Expression stability of six housekeeping genes: A proposal for resistance gene quantification studies of Pseudomonas aeruginosa by real-time quantitative RT-PCR. Journal of Medical Microbiology, 52, 403-408. https://doi:10.1099/ jmm.0.05132-0 google scholar
  • Sieuwerts, A. M., Usher, P.A., Meijer-van Gelder, M. E., Timmer-mans, M., Martens, J.W., Brünner, N., ...Foakens, J. A. (2007). Con-centrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer. Clinical Chemistry, 53, 1280-1288. https://doi:10.1373/ clinchem.2006.082800. google scholar
  • Talvensaari-Mattila, A., & Paakkö, P., Turpeenniemi-Hujanen, T. (2003) Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. British Journal of Cancer, 89, 12701275. https://doi:10.1038/sj.bjc.6601238 google scholar
  • Talvensaari-Mattila, A., & Turpeenniemi-Hujanen, T. (2005). High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma. Breast Cancer Research and Treatment, 89, 29-34. https://doi.org/10.1007/s10549-004-1006-8 google scholar
  • Ünçel., M, Aköz., G, Yıldırım., Z, Pişkin., G, Değirmenci M, Kahraman DS, . Diniz., G. (2015). Evaluation of clinicopathological features of breast cancer according to the molecular subtypes. Journal of Tepecik Education and Research Hospital, 25, 151-156. https:// doi:10.5222/terh.2015.151 google scholar
  • Wu, Z. S., Wu, Q., Yang, J. H., Wang, H. Q., Ding, X. D., Yang, F., & Xu, X. C. (2008). Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. International Journal of Cancer, 122, 2050-2056. https://doi.org/10.1002/ijc.23337 google scholar
  • Würtz, S. 0., Schrohl, A. S., Mouridsen, H., & Brünner, N. (2008). TIMP-1 as a tumor marker in breast cancer - An update. Acta Oncolog-ica (Madr), 47, 580-590. https://doi:10.1080/02841860802022976. Würtz S. 0., Moller, S., Mouridsen, H., Hertel, P B., Friis, E., & Brünner N. (2008). Plasma and serum levels of tissue inhibitor of metal-loproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study. Molecular & Cellular Proteomics, 7, 424-430. https://doi:10.1074/mcp.M700305-MCP200. google scholar
  • Yadav, L., Puri, N., Rastogi. V., Satpute, P., Ahmad, R., & Kaur, G. (2014). Matrix metalloproteinases and cancer - Roles in threat and therapy. The Asian Pacific Journal of Cancer Prevention, 15, 10851091. http://dx.doi.org/10.7314/APJCP.2014.15.3.1085 google scholar
  • Zhang, M., Teng, X., Guo, X., Li, Z., Han, J., & Yao, L. (2013). Expres-sion of tissue levels of matrix metalloproteinases and their inhibi-tors in breast cancer. The Breast, 22, 330-334. https://doi:10.1016/j. breast.2012.08.002. google scholar
There are 32 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Original Article
Authors

Seda Eren Keskin 0000-0002-8315-646X

Deniz Sünnetçi Akkoyunlu 0000-0001-9297-8222

Mehtap Yılmaz 0000-0003-3698-1640

Turgay Şimşek 0000-0002-5733-6301

Sertaç Güler 0000-0003-1616-9436

Naci Çine 0000-0001-9063-1073

Zafer Cantürk 0000-0002-0042-9742

Hakan Savlı

Publication Date August 30, 2023
Submission Date January 5, 2022
Published in Issue Year 2023

Cite

APA Eren Keskin, S., Sünnetçi Akkoyunlu, D., Yılmaz, M., Şimşek, T., et al. (2023). Quantification of MMP-2 and TIMP-1 expressions in breast cancer. İstanbul Journal of Pharmacy, 53(2), 211-218. https://doi.org/10.26650/IstanbulJPharm.2023.1053089
AMA Eren Keskin S, Sünnetçi Akkoyunlu D, Yılmaz M, Şimşek T, Güler S, Çine N, Cantürk Z, Savlı H. Quantification of MMP-2 and TIMP-1 expressions in breast cancer. iujp. August 2023;53(2):211-218. doi:10.26650/IstanbulJPharm.2023.1053089
Chicago Eren Keskin, Seda, Deniz Sünnetçi Akkoyunlu, Mehtap Yılmaz, Turgay Şimşek, Sertaç Güler, Naci Çine, Zafer Cantürk, and Hakan Savlı. “Quantification of MMP-2 and TIMP-1 Expressions in Breast Cancer”. İstanbul Journal of Pharmacy 53, no. 2 (August 2023): 211-18. https://doi.org/10.26650/IstanbulJPharm.2023.1053089.
EndNote Eren Keskin S, Sünnetçi Akkoyunlu D, Yılmaz M, Şimşek T, Güler S, Çine N, Cantürk Z, Savlı H (August 1, 2023) Quantification of MMP-2 and TIMP-1 expressions in breast cancer. İstanbul Journal of Pharmacy 53 2 211–218.
IEEE S. Eren Keskin, “Quantification of MMP-2 and TIMP-1 expressions in breast cancer”, iujp, vol. 53, no. 2, pp. 211–218, 2023, doi: 10.26650/IstanbulJPharm.2023.1053089.
ISNAD Eren Keskin, Seda et al. “Quantification of MMP-2 and TIMP-1 Expressions in Breast Cancer”. İstanbul Journal of Pharmacy 53/2 (August 2023), 211-218. https://doi.org/10.26650/IstanbulJPharm.2023.1053089.
JAMA Eren Keskin S, Sünnetçi Akkoyunlu D, Yılmaz M, Şimşek T, Güler S, Çine N, Cantürk Z, Savlı H. Quantification of MMP-2 and TIMP-1 expressions in breast cancer. iujp. 2023;53:211–218.
MLA Eren Keskin, Seda et al. “Quantification of MMP-2 and TIMP-1 Expressions in Breast Cancer”. İstanbul Journal of Pharmacy, vol. 53, no. 2, 2023, pp. 211-8, doi:10.26650/IstanbulJPharm.2023.1053089.
Vancouver Eren Keskin S, Sünnetçi Akkoyunlu D, Yılmaz M, Şimşek T, Güler S, Çine N, Cantürk Z, Savlı H. Quantification of MMP-2 and TIMP-1 expressions in breast cancer. iujp. 2023;53(2):211-8.